| Schedule of financial assets and liabilities measured at fair value on a recurring basis |
The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands): | | | | | | | | | | | | | | | Fair Value Measurements as of March 31, 2026 using: | | | Quoted Prices in | | Significant Other | | Significant | | | | | | Active Markets for | | Observable | | Unobservable | | | | | | Identical Assets | | Inputs | | Inputs | | | | | | (Level 1) | | (Level 2) | | (Level 3) | | Total | Assets: | | | | | | | | | | | | | Cash equivalents: | | | | | | | | | | | | | Money market funds | | $ | 49,835 | | $ | — | | $ | — | | $ | 49,835 | U.S. treasury bills | | | 25,505 | | | — | | | — | | | 25,505 | Total cash equivalents | | | 75,340 | | | — | | | — | | | 75,340 | Exarafenib milestone asset (Note 6) | | | — | | | — | | | 3,704 | | | 3,704 | Investment in equity securities | | | 494 | | | — | | | — | | | 494 | Castle Creek PRV Interest (Note 4) | | | — | | | — | | | — | | | — | Castle Creek warrants (Note 4) | | | — | | | — | | | 709 | | | 709 | Total financial assets | | $ | 75,834 | | $ | — | | $ | 4,413 | | $ | 80,247 | Liabilities: | | | | | | | | | | | | | Exarafenib milestone contingent consideration (Note 6) | | $ | — | | $ | — | | $ | 3,704 | | $ | 3,704 | Total financial liabilities | | $ | — | | $ | — | | $ | 3,704 | | $ | 3,704 |
| | | | | | | | | | | | | | | Fair Value Measurements as of December 31, 2025 using: | | | Quoted Prices in | | Significant Other | | Significant | | | | | | Active Markets for | | Observable | | Unobservable | | | | | | Identical Assets | | Inputs | | Inputs | | | | | | (Level 1) | | (Level 2) | | (Level 3) | | Total | Assets: | | | | | | | | | | | | | Cash equivalents: | | | | | | | | | | | | | Money market funds | | $ | 41,810 | | $ | — | | $ | — | | $ | 41,810 | U.S. treasury bills | | | 6,330 | | | — | | | — | | | 6,330 | Total cash equivalents | | | 48,140 | | | — | | | — | | | 48,140 | Exarafenib milestone asset (Note 6) | | | — | | | — | | | 3,600 | | | 3,600 | Investment in equity securities | | | 382 | | | — | | | — | | | 382 | Castle Creek PRV Interest (Note 4) | | | — | | | — | | | — | | | — | Castle Creek warrants (Note 4) | | | — | | | — | | | 697 | | | 697 | Total financial assets | | $ | 48,522 | | $ | — | | $ | 4,297 | | $ | 52,819 | Liabilities: | | | | | | | | | | | | | Exarafenib milestone contingent consideration (Note 6) | | $ | — | | $ | — | | $ | 3,600 | | $ | 3,600 | Share-based liability (Note 12) | | | — | | | — | | | 3,197 | | | 3,197 | Total financial liabilities | | $ | — | | $ | — | | $ | 6,797 | | $ | 6,797 |
|